Abstract 115P
Background
Cholangiocarcinoma is the most common primary cancer of liver in North-Eastern region of Thailand. Human epidermal growth factor receptor-2 (HER-2) overexpression is a poor prognostic factor of many types of cancer but there is limited data in cholangiocarcinoma. This study aimed to investigate prevalence of HER-2 overexpression in cholangiocarcinoma and analyzed its association with overall survival and clinicopathological features.
Methods
This study was retrospective cohort analytical single-centered study which included adult patients with cholangiocarcinoma in Srinagarind hospital, Khon Kaen, Thailand. HER-2 expression was classified as positive and negative group. Prevalence of HER-2 overexpression was presented with percentage and 95% confidence interval (95% CI).
Results
A total of 93 cases, of which 71% were male, were included. Mean age was 63 and 62 years in HER-2 positive and negative groups, respectively. The proportion of intrahepatic was more than extrahepatic cholangiocarcinoma (72% vs 28%). HER-2 positive was revealed 10.8% (95% CI 5.3% to 18.9%), composed of 9 cases (13.4%) of patients with intrahepatic cholangiocarcinoma and 1 case (3.8%) of patients with extrahepatic cholangiocarcinoma. The prevalence of HER-2 staining intensity 2+ and 1+ were 14.0% (13 cases) and 15.1% (14 cases), respectively. Median overall survival was not reach in HER-2 positive group compared with 30.9 months in negative group. (hazard ratio 0.39; 95% CI 0.12 to 1.21; p 0.089). This study could not demonstrate association between HER-2 positive and any clinicopathological features.
Conclusions
Among patients with cholangiocarcinoma, 1 of 10 cases had HER-2 overexpression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was granted by Faculty of Medicine, Khon Kaen University, Thailand (Grant Number IN64140).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
99P - Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma
Presenter: Kazuaki Harada
Session: Poster viewing 02
100P - A prospective single arm study evaluating the outcome of neoadjuvant chemotherapy in locally advanced/border line resectable gall bladder cancer
Presenter: Pulkit Nag
Session: Poster viewing 02
101P - Cachexia index and sarcopenia in patients with advanced gastrointestinal cancer treated with chemotherapy during exercise intervention
Presenter: Song Ee Park
Session: Poster viewing 02
102P - A real-world study comparing apatinib combined with irinotecan versus irinotecan as second-line or above therapy in patients with advanced or metastatic gastric cancer
Presenter: Caiyun Nie
Session: Poster viewing 02
103P - Concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: A meta-analysis
Presenter: Jianquan Yang
Session: Poster viewing 02
104P - A multi-institutional epidemiological and oncological profile of gastrointestinal stromal tumors in the Lebanese population
Presenter: Mohamad Hadi El Charif
Session: Poster viewing 02
105P - The efficacy of nivolumab monotherapy for advanced gastric cancer depends on the HER2 status
Presenter: Yuichiro Nishibori
Session: Poster viewing 02
106P - Clinicopathologic and prognostic significance of FBXL5 expression in hepatocellular carcinoma
Presenter: Yoon Ah Cho
Session: Poster viewing 02
107P - Preliminary result of anatomical hepatectomy on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma
Presenter: Xiaozhun Huang
Session: Poster viewing 02